Urinary protein biomarker panel for the detection of recurrent bladder cancer

Charles J. Rosser, Myron Chang, Yunfeng Dai, Shanti Ross, Lourdes Mengual, Antonio Alcaraz, Steven Goodison

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: Up to 70% of patients with non-muscle-invasive bladder cancer (NMIBC) experience disease recurrence, making it one of the most prevalent cancers in the United States. The purpose of this study was to test the performance of a multiplex urinary biomarker assay for the monitoring of voided urine for recurrent bladder cancer. Methods: This retrospective, multicenter study included a total of 125 subjects with a history of bladder cancer. Voided urine specimens were collected before procedure from these subjects (53 with confirmed tumor recurrence and 72 with confirmed non-tumor recurrence) for analysis. A prediction rule generated from the performance characteristics of 10 single biomarkers (IL8, MMP9, MMP10, SERPINA1, VEGFA, ANG, CA9, APOE, SERPINE1, and SDC1) was measured using ELISA. The diagnostic performance of the biomarker panel was assessed using receiver operator curves (ROC) and descriptive statistical values (e.g., sensitivity and specificity). Results: The combination of all 10 biomarkers outperformed any single biomarker with a calculated AUROC for the diagnostic panel of 0.904 [95% confidence interval (CI), 0.853-0.956]. The multiplex assay achieved an overall sensitivity of 79% and specificity of 88% for recurrent bladder cancer and significantly outperformed the Urovysion cytogenetic assay (sensitivity 42%, specificity 94%) and voided urinary cytology (sensitivity 33%, specificity 90%). Conclusions: A diagnostic panel of 10 urinary biomarkers that accurately detects primary bladder cancer also performs well for the detection of recurrent bladder cancer. Impact: The identification of a reliable urine-based surveillance and detection assay would be of benefit to both patients and the healthcare system.

Original languageEnglish (US)
Pages (from-to)1340-1345
Number of pages6
JournalCancer Epidemiology Biomarkers and Prevention
Volume23
Issue number7
DOIs
StatePublished - Jan 1 2014

Fingerprint

Urinary Bladder Neoplasms
Biomarkers
Sensitivity and Specificity
Proteins
Urine
Recurrence
Apolipoproteins E
Interleukin-8
Cytogenetics
Multicenter Studies
Cell Biology
Neoplasms
Retrospective Studies
Enzyme-Linked Immunosorbent Assay
Confidence Intervals
Delivery of Health Care

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Urinary protein biomarker panel for the detection of recurrent bladder cancer. / Rosser, Charles J.; Chang, Myron; Dai, Yunfeng; Ross, Shanti; Mengual, Lourdes; Alcaraz, Antonio; Goodison, Steven.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 23, No. 7, 01.01.2014, p. 1340-1345.

Research output: Contribution to journalArticle

Rosser, Charles J. ; Chang, Myron ; Dai, Yunfeng ; Ross, Shanti ; Mengual, Lourdes ; Alcaraz, Antonio ; Goodison, Steven. / Urinary protein biomarker panel for the detection of recurrent bladder cancer. In: Cancer Epidemiology Biomarkers and Prevention. 2014 ; Vol. 23, No. 7. pp. 1340-1345.
@article{0362cc4ae21441baad11132a833c058b,
title = "Urinary protein biomarker panel for the detection of recurrent bladder cancer",
abstract = "Background: Up to 70{\%} of patients with non-muscle-invasive bladder cancer (NMIBC) experience disease recurrence, making it one of the most prevalent cancers in the United States. The purpose of this study was to test the performance of a multiplex urinary biomarker assay for the monitoring of voided urine for recurrent bladder cancer. Methods: This retrospective, multicenter study included a total of 125 subjects with a history of bladder cancer. Voided urine specimens were collected before procedure from these subjects (53 with confirmed tumor recurrence and 72 with confirmed non-tumor recurrence) for analysis. A prediction rule generated from the performance characteristics of 10 single biomarkers (IL8, MMP9, MMP10, SERPINA1, VEGFA, ANG, CA9, APOE, SERPINE1, and SDC1) was measured using ELISA. The diagnostic performance of the biomarker panel was assessed using receiver operator curves (ROC) and descriptive statistical values (e.g., sensitivity and specificity). Results: The combination of all 10 biomarkers outperformed any single biomarker with a calculated AUROC for the diagnostic panel of 0.904 [95{\%} confidence interval (CI), 0.853-0.956]. The multiplex assay achieved an overall sensitivity of 79{\%} and specificity of 88{\%} for recurrent bladder cancer and significantly outperformed the Urovysion cytogenetic assay (sensitivity 42{\%}, specificity 94{\%}) and voided urinary cytology (sensitivity 33{\%}, specificity 90{\%}). Conclusions: A diagnostic panel of 10 urinary biomarkers that accurately detects primary bladder cancer also performs well for the detection of recurrent bladder cancer. Impact: The identification of a reliable urine-based surveillance and detection assay would be of benefit to both patients and the healthcare system.",
author = "Rosser, {Charles J.} and Myron Chang and Yunfeng Dai and Shanti Ross and Lourdes Mengual and Antonio Alcaraz and Steven Goodison",
year = "2014",
month = "1",
day = "1",
doi = "10.1158/1055-9965.EPI-14-0035",
language = "English (US)",
volume = "23",
pages = "1340--1345",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Urinary protein biomarker panel for the detection of recurrent bladder cancer

AU - Rosser, Charles J.

AU - Chang, Myron

AU - Dai, Yunfeng

AU - Ross, Shanti

AU - Mengual, Lourdes

AU - Alcaraz, Antonio

AU - Goodison, Steven

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Up to 70% of patients with non-muscle-invasive bladder cancer (NMIBC) experience disease recurrence, making it one of the most prevalent cancers in the United States. The purpose of this study was to test the performance of a multiplex urinary biomarker assay for the monitoring of voided urine for recurrent bladder cancer. Methods: This retrospective, multicenter study included a total of 125 subjects with a history of bladder cancer. Voided urine specimens were collected before procedure from these subjects (53 with confirmed tumor recurrence and 72 with confirmed non-tumor recurrence) for analysis. A prediction rule generated from the performance characteristics of 10 single biomarkers (IL8, MMP9, MMP10, SERPINA1, VEGFA, ANG, CA9, APOE, SERPINE1, and SDC1) was measured using ELISA. The diagnostic performance of the biomarker panel was assessed using receiver operator curves (ROC) and descriptive statistical values (e.g., sensitivity and specificity). Results: The combination of all 10 biomarkers outperformed any single biomarker with a calculated AUROC for the diagnostic panel of 0.904 [95% confidence interval (CI), 0.853-0.956]. The multiplex assay achieved an overall sensitivity of 79% and specificity of 88% for recurrent bladder cancer and significantly outperformed the Urovysion cytogenetic assay (sensitivity 42%, specificity 94%) and voided urinary cytology (sensitivity 33%, specificity 90%). Conclusions: A diagnostic panel of 10 urinary biomarkers that accurately detects primary bladder cancer also performs well for the detection of recurrent bladder cancer. Impact: The identification of a reliable urine-based surveillance and detection assay would be of benefit to both patients and the healthcare system.

AB - Background: Up to 70% of patients with non-muscle-invasive bladder cancer (NMIBC) experience disease recurrence, making it one of the most prevalent cancers in the United States. The purpose of this study was to test the performance of a multiplex urinary biomarker assay for the monitoring of voided urine for recurrent bladder cancer. Methods: This retrospective, multicenter study included a total of 125 subjects with a history of bladder cancer. Voided urine specimens were collected before procedure from these subjects (53 with confirmed tumor recurrence and 72 with confirmed non-tumor recurrence) for analysis. A prediction rule generated from the performance characteristics of 10 single biomarkers (IL8, MMP9, MMP10, SERPINA1, VEGFA, ANG, CA9, APOE, SERPINE1, and SDC1) was measured using ELISA. The diagnostic performance of the biomarker panel was assessed using receiver operator curves (ROC) and descriptive statistical values (e.g., sensitivity and specificity). Results: The combination of all 10 biomarkers outperformed any single biomarker with a calculated AUROC for the diagnostic panel of 0.904 [95% confidence interval (CI), 0.853-0.956]. The multiplex assay achieved an overall sensitivity of 79% and specificity of 88% for recurrent bladder cancer and significantly outperformed the Urovysion cytogenetic assay (sensitivity 42%, specificity 94%) and voided urinary cytology (sensitivity 33%, specificity 90%). Conclusions: A diagnostic panel of 10 urinary biomarkers that accurately detects primary bladder cancer also performs well for the detection of recurrent bladder cancer. Impact: The identification of a reliable urine-based surveillance and detection assay would be of benefit to both patients and the healthcare system.

UR - http://www.scopus.com/inward/record.url?scp=84904011624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904011624&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-14-0035

DO - 10.1158/1055-9965.EPI-14-0035

M3 - Article

VL - 23

SP - 1340

EP - 1345

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 7

ER -